Skye Bioscience Shares Are Trading Higher After the Company Announced That It Started Screening Patients for a Phase 2 Clinical Trial of Nimacimab.
Skye Bioscience Shares Are Trading Higher After the Company Announced That It Started Screening Patients for a Phase 2 Clinical Trial of Nimacimab.
Skye生物科技股份的股價上漲，因爲公司宣佈已開始篩選參與尼瑪西單抗第2期臨床試驗的患者。
Skye Bioscience Shares Are Trading Higher After the Company Announced That It Started Screening Patients for a Phase 2 Clinical Trial of Nimacimab.
Skye生物科技股份的股價上漲，因爲公司宣佈已開始篩選參與尼瑪西單抗第2期臨床試驗的患者。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。